<p class="abstract"><strong>Background:</strong> A newer itraconazole formulation i.e., super bioavailable has been launched recently in India which is claimed to overcome all the pharmacokinetic challenges faced with conventional itraconazole. The present retrospective data analysis was undertaken evaluate effectiveness and safety of comparison treatment dermatophytosis India...

The aim of the present study is to assess the clinical efficacy of a phytocompound with antimicotic properties (K-712, with the following 100 mg composition: 10 mg of oleoresin from Pseudowintera colorata at 30 percent concentration in Polygodial together with trace amounts of Olea europea) in recurrent vulvo-vaginal candidiasis (RVVC) as compared to an azole drug during a 12-month period: 6 mo...

Systemic antifungal are used in severe tinea versicolor or in cases not responding to topical therapy, different regimen modalities with different efficacy result and cure rates have been tried in this experiment. To compare different modalities regimens of the azoles group in the treatment of tinea versicolor. This study was carried out in Department of dermatology and venereology in AL –KINDY...

The objective of the work is to formulate, optimize and evaluate “Itraconazole nanosuspension as aerosol foam formulation” for the treatment of skin diseases such as Cellulitis, Erysipelas, Impeigo and Blastomycosis, Histoplasmosis, Onchomycosis, etc. The solubility of poorly soluble itraconazole can be improved through nanosuspension process and also the absorption rate and bioavailability of ...

Itraconazole is an orally active triazole antifungal drug which has demonstrated a broad spectrum of activity. It is a potent inhibitor of most human fungal pathogens including Crypro,coccus neoformans (Grant and Clissold, 1989). A recent study by Denning et a1 (1989) revealed the usefulness of itraconazole therapy for cryptococcosis. We also experienced the good result of itra,conazole in the ...

The effects of itraconazole on ergosterol biosynthesis were investigated in a series of 16 matched clinical Candida albicans isolates which had been previously analyzed for mechanisms of resistance to azoles (D. Sanglard, K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother., 39:2378-2386, 1995). Under control conditions, all isolates contained ergosterol as...

Simple, low-cost PCR/PCR-restriction fragment length polymorphism (RFLP) assays targeting cyp51A promoter and codon 98 regions were developed for the detection of triazole-resistant Aspergillus fumigatus strains carrying TR34/L98H mutations. The assays were evaluated using 40 itraconazole-susceptible isolates and 35 itraconazole-resistant isolates. The prevalence of TR34/L98H mutations in clini...

The MICs of amphotericin B and itraconazole for 230 isolates of Aspergillus spp., comprising 156 Aspergillus fumigatus, 20 Aspergillus terreus, 22 Aspergillus flavus, 17 Aspergillus nidulans and 15 Aspergillus niger, were determined by a broth microdilution method with RPMI 1640 medium. No isolate was detected with an MIC of amphotericin B >2 mg/L. Itraconazole MICs >16 mg/L were detected for f...

Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts. In all instances, the voriconazole MICs were lower than those of fluconazole. In most instances, the MICs were l...

We report the in-vitro susceptibility of 27 clinical isolates of Scedosporium apiospermum and 43 of Scedosporium prolificans. S. apiospermum was resistant to fluconazole and flucytosine, with variable susceptibility to amphotericin B, itraconazole, ketoconazole and susceptible to miconazole. Voriconazole was much more active than fluconazole and flucytosine, more active than amphotericin B, itr...